

**pembrolizumab 2 mg/kg -
DOCEtaxel 75 - CARBOplatin
AUC 5 Regimen: Part I**

ARIA Protocol Name: Pembro2mg/kg Doce75mg/m2 CarboAUC5
Adult Chemotherapy - Medical Oncology
Neoadjuvant Triple Negative Breast Cancer Therapy



CC7300 0550 04 2025

Name: _____

HCN: _____

Date of Birth: _____

Allergies:

No Known

Date: DD/MONTH/YYYY

Planned Administration Date: DD/MONTH/YYYY

Cycle _____ of _____

Cycle Duration: 21 days

Date of previous cycle: DD/MONTH/YYYY

MAY PROCEED WITH DOSES AS WRITTEN IF:

- ANC **greater than or equal to** $1.5 \times 10^9/L$ and platelets **greater than or equal to** $100 \times 10^9/L$, otherwise notify Medical Oncologist.
- LFT's and Bilirubin assessed.
- Creatinine clearance assessed.
- Thyroid function assessed.

PREMEDICATIONS (FOR COMMUNITY PHARMACY):

dexamethasone 8 mg PO bid for 3 days, starting one day prior to DOCEtaxel.

Patient must receive a minimum of three doses prior to receiving treatment.

Other: _____

PREMEDICATIONS (FOR HOSPITAL PHARMACY):

fosaprepitant 150 mg IV in 150 mL normal saline over 30 minutes on day 1

ondansetron 8 mg PO on day 1

Other: _____

PLEASE REFER TO CHEMOTHERAPY LETTER WHEN ORDERING SUPPORTIVE MEDICATIONS FOR THIS PATIENT

Authorized Prescriber: _____ Date: DD/MONTH/YYYY Time: _____

Authorized Prescriber's Signature: _____ ID #: _____

Nurse's Name: _____ Date: DD/MONTH/YYYY Time: _____

Nurse's Signature: _____

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.

Doctor's Order Sheet

**pembrolizumab 2 mg/kg -
DOCEtaxel 75 - CARBOplatin
AUC 5 Regimen: Part II**

ARIA Protocol Name: Pembro2mg/kg Doce75mg/m2 CarboAUC5

Adult Chemotherapy - Medical Oncology

Neoadjuvant Triple Negative Breast Cancer Therapy



CC7300 0550 04 2025

Name: _____

HCN: _____

Date of Birth: _____

Weight: _____ kg Height: _____ cm Body Surface Area (BSA) = _____

CHEMOTHERAPY (FOR HOSPITAL PHARMACY):

pembrolizumab 2 mg/kg X Weight (kg) = _____ **mg (maximum dose 200 mg)**

IV in 50 mL normal saline over 30 minutes on day 1

DOCEtaxel 75 mg/m² X BSA = _____ **mg**

Dose modification: **DOCEtaxel 75 mg/m²** X BSA - _____ % = _____ **mg**

IV in 250 mL normal saline PVC Free with 0.2 micron in-line filter over 60 minutes on day 1

CARBOplatin AUC 5 = _____ **mg**

Dose modification: **CARBOplatin AUC 5** - _____ % = _____ **mg**

IV in 250 mL normal saline over 30 minutes on day 1

POST-CHEMOTHERAPY (FOR COMMUNITY PHARMACY):

filgrastim (Brand: _____) _____ **mcg** subcutaneous daily for 7 days starting 24-48 hours post chemotherapy

peg-filgrastim (Brand: _____) **6 mg** subcutaneous for one dose 24-48 hours post chemotherapy

PLEASE REFER TO CHEMOTHERAPY LETTER WHEN ORDERING SUPPORTIVE MEDICATIONS FOR THIS PATIENT

Authorized Prescriber: _____ Date: DD/MONTH/YYYY Time: _____

Authorized Prescriber's Signature: _____ ID #: _____

Nurse's Name: _____ Date: DD/MONTH/YYYY Time: _____

Nurse's Signature: _____

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.